You are viewing: Brazil AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The Brazil AI in Life Science Market was valued at $419.1 Million in 2026 and projected to reach to $1243.6 Million by 2031, representing a compound annual growth rate of 24.3%. Brazil's AI in Life Science market is positioned for substantial growth, driven by increasing investments in healthcare technology, rising demand for personalized medicine, and the country's strong pharmaceutical manufacturing base.

Brazil AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Brazil AI in Life Science Market Trends and Insights

  • This represents a compound annual growth rate of 24.3%, reflecting strong adoption of artificial intelligence technologies across Brazil's pharmaceutical, biotechnology, and healthcare research sectors.
  • Brazil's position as Latin America's largest economy and its growing investment in healthcare innovation are driving this accelerated market penetration. The Brazilian life science industry is increasingly leveraging AI for drug discovery, clinical trial optimization, and personalized medicine applications.
  • Brazil's expanding research infrastructure, coupled with government initiatives to modernize healthcare delivery, creates favorable conditions for AI integration.
  • Between 2026 and 2031, Brazil is expected to capture significant market share within Latin America, driven by rising demand for computational solutions in genomics, diagnostics, and therapeutic development. Brazil's market growth outpaces many emerging economies, supported by partnerships between local institutions and global AI vendors.
  • The country's regulatory environment and skilled workforce in biotechnology are positioning Brazil as a regional hub for AI-driven life science innovation through 2031..

Key Market Statistics

  • CAGR (2026-2031) 24.3% CAGR
  • Market Size, 2026 ~USD 419.1 Million
  • Forecast, 2031 ~USD 1243.6 Million
  • Country Brazil

Brazil AI in Life Science Market Overview

Rapid Market Expansion :

Brazil's AI in Life Science market is projected to grow from $419.1 million in 2026 to $1,243.6 million by 2031, representing a 24.3% CAGR and demonstrating strong momentum in the region's healthcare innovation ecosystem.

Latin America Leadership :

As Latin America's largest economy, Brazil is driving regional adoption of AI technologies in pharmaceutical research, clinical trials, and biotechnology development, positioning itself as a hub for life science innovation.

Pharmaceutical & Biotech Growth :

Brazil's robust pharmaceutical and biotechnology sectors are increasingly integrating AI for drug discovery, personalized medicine, and healthcare analytics, creating significant opportunities for technology providers and service vendors.

Healthcare Infrastructure Investment :

Growing government and private sector investments in Brazil's healthcare infrastructure are accelerating AI adoption across hospitals, research institutions, and diagnostic centers, supporting market expansion.

Brazil AI in Life Science Market Dynamics

  • The 24.3% CAGR reflects growing adoption among research institutions, hospitals, and biotech companies seeking to enhance drug development efficiency and patient outcomes. The market's expansion is supported by Brazil's skilled workforce, favorable regulatory environment for healthcare innovation, and strategic partnerships between local and international life science organizations.
  • By 2031, the market is expected to reach $1,243.6 million, establishing Brazil as a key player in Latin America's AI-driven healthcare transformation and attracting continued investment from global technology and pharmaceutical companies..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • Brazil's AI in Life Science market will nearly triple from $419.1M (2026) to $1,243.6M (2031), driven by 24.3% CAGR.
    • Brazil leads Latin America in AI adoption within life sciences, supported by strong research institutions and government healthcare modernization initiatives.
    • Brazil's market growth is fueled by increasing demand for AI-powered drug discovery, clinical trial optimization, and personalized medicine solutions.
    • Brazil's skilled biotechnology workforce and regulatory framework position the country as a regional innovation hub for AI-driven life science applications.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    Brazil AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    BRAZIL: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & GOVERNMENT LABORATORIES23.228.23543.753.967.183.1101.723.8
    BIOTECHNOLOGY COMPANIES62.97796.3121150.3188.4234.8289.224.6
    CRO & CDMO38.546.958.372.889.9112.1139170.323.9
    DIAGNOSTIC COMPANIES28.735.143.85568.185.3106130.324.4
    OTHER END USERS12.815.619.32429.536.54554.923.3
    PHARMACEUTICAL COMPANIES109.1133.4166.6209259.3324.7404.1497.224.4
    TOTAL275.1336.2419.1525.4651814.210121243.624.3

    Target Audience

    • Pharmaceutical & Biotech Companies : Brazilian and international pharma/biotech firms need market data to assess AI investment opportunities, benchmark R&D spending, and identify technology partnerships to accelerate drug discovery and development timelines.
    • AI & Healthcare Technology Vendors : Software and AI solution providers require Brazil-specific market sizing and growth forecasts to prioritize market entry, allocate sales resources, and develop localized product offerings for life science applications.
    • Healthcare Investors & PE Firms : Investment firms and venture capitalists need validated market data on Brazil's AI life science sector to evaluate portfolio opportunities, assess growth potential, and make informed funding decisions in the region.
    • Hospital & Research Institution Leaders : Brazilian hospital networks and research centers require market intelligence to justify AI technology investments, benchmark adoption rates, and identify best-in-class solutions for clinical and research applications.
    • Government & Policy Makers : Brazilian health ministry officials and policy makers need market insights to develop healthcare innovation strategies, allocate R&D funding, and create regulatory frameworks supporting AI adoption in life sciences.

    Key Companies in the Brazil AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation for Brazil ($419.1M in 2026, $1,243.6M in 2031) with verified 24.3% CAGR to support investment decisions, business planning, and competitive positioning in this high-growth market.
    • Regional Competitive Intelligence : Understand Brazil's unique market dynamics, local pharmaceutical and biotech adoption patterns, and competitive landscape to identify opportunities and develop targeted go-to-market strategies for life science AI solutions.
    • Sector-Specific Insights : Access detailed analysis of AI applications across Brazil's pharmaceutical research, clinical trials, personalized medicine, and diagnostic sectors to align product development and marketing with actual market demand.
    • Investment & Partnership Opportunities : Identify high-potential segments, emerging players, and partnership opportunities within Brazil's life science ecosystem to guide M&A strategies, venture investments, and strategic collaborations.
    • Regulatory & Market Entry Guidance : Leverage Brazil-specific market intelligence to navigate regulatory requirements, understand healthcare infrastructure readiness, and develop compliant market entry strategies for AI life science solutions.

    Frequently asked questions

    What is the projected market size of AI in Life Science in Brazil by 2031?

    Brazil's AI in Life Science market is projected to reach $1,243.6 million by 2031, up from $419.1 million in 2026.

    What is the CAGR for Brazil's AI in Life Science market?

    Brazil's AI in Life Science market is expected to grow at a compound annual growth rate of 24.3% between 2026 and 2031.

    What are the primary drivers of AI adoption in Brazil's life science sector?

    Brazil's AI adoption is driven by government healthcare modernization initiatives, expanding research infrastructure, partnerships with global AI vendors, and increasing demand for drug discovery and personalized medicine solutions.

    How does Brazil's market growth compare to the global AI in Life Science market?

    Brazil's 24.3% CAGR is slightly lower than the global 26.3% CAGR, but Brazil maintains strong regional leadership within Latin America for AI life science adoption.

    What applications of AI are most prevalent in Brazil's life science market?

    Brazil's life science sector primarily leverages AI for drug discovery, clinical trial optimization, genomics analysis, diagnostics, and personalized medicine development.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status